Avalere Presents First Real-World Evidence on Medicare Patients’ CAR-T Experiences at ASH Press Briefing

Summary

On Saturday, December 7, Karl Kilgore discussed “Medicare Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma: A First Real-World Look at Patient Characteristics, Healthcare Utilization and Costs” during a press briefing at the American Society of Hematology’s Annual Meeting.

Please note: This is an archived post. Some of the information and data discussed in this article may be out of date. It is preserved here for historical reference but should not be used as the basis for business decisions. Please see our main Insights section for more recent posts.

The objective of the retrospective observational study was to describe the demographic and clinical characteristics of Medicare patients receiving CAR-T therapy, and compare real-world healthcare utilization, costs, and outcomes pre- and post-therapy. The team used the Centers for Medicare and Medicaid Services (CMS) 100% Medicare Fee-for-Service Part A and B claims data, which Avalere accesses through a data use agreement with CMS, representing 207 patients who received CAR-T in 2017 and 2018 with 6 months of data pre and post CAR-T procedure.

Key findings include:

Median age is 71 and older than previously observed in clinical trial literature
51% of patients had 1 or more chronic conditions that, in some cases could have excluded them from clinical trials
The median length of stay in the hospital for the CAR-T procedure was 17 days
Patients spent 17% less time in the hospital 6 months post CAR-T procedure compared to the 6 months prior to having it
Overall healthcare costs, exclusive of the costs associated with the CAR-T procedure itself, were reduced by 39% after CAR-T
CMS, on average, is reimbursing PPS hospitals treating with CAR T ~$422K and ~$467K in the inpatient and outpatient settings respectively
Limitations of this study include a relatively small sample of Medicare patients which may not represent other US populations and a relatively short look-back and follow-up period which may be insufficient to fully understand longer term outcomes

Karl Kilgore will be presenting the full research on Monday, December 9, at 2:45 PM ET.

Read the research presentation.

Funding for this research was provided by Gilead Sciences, Inc., and Kite Pharma, Inc.

To receive Avalere updates, connect with us.

Find out the top 2020 healthcare trends to watch.